Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06802081 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Study acronym: TIRO-AF
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2026 to Dec 31, 2026
    • Study completion date: Dec 31, 2026 to Jun 1, 2027
    • Study description revised
    • Eligibility criteria expanded, about 1 word
    v4
  2. Start date changed from estimate of Mar 31, 2025 to Apr 8, 2025
    • Eligibility criteria shortened, about 14 words
    • Site contact updated
    v3
  3. Start date: Mar 3, 2025 to Mar 31, 2025
    • Eligibility criteria expanded, about 14 words
    • Study description revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Cleveland Clinic
212 trials monitored
See 33 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Atrial Fibrillation
1,182 trials monitored
See 50 trials at risk
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Trial Details
NCT Number NCT06802081
Lead Sponsor The Cleveland Clinic
Conditions
(from sponsor)		 Atrial Fibrillation, Obesity
Related terms Atrial Fibrillation, Obesity
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov